Systematic testing of groups at increased risk of SARS-CoV-2: an affordable and reasonable approach
In a new cost-analysis study, researchers recommend widespread testing of...
Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19
Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations
COVID-19 Q&A on dealing with pandemic fatigue
“We need to strike a balance and take our anxiety down from an unhealthy to a manageable level,” says researcher Jason Harley
New study shows that persistence of ADHD into adulthood is an important predictor of car crash risk
RI-MUHC researcher Dr. Lily Hechtman is senior author of a 20-year study
Lashanda Skerritt awarded Vanier Canada Graduate Scholarship
“I am constantly reminded that community involvement and advocacy are important drivers of scientific and medical knowledge,” says the RI-MUHC...
Research suggests greater access to specific HIV and tuberculosis medications is needed worldwide
Postdoctoral fellows at the RI-MUHC carried out primary statistical analyses for study published in The Lancet
Inappropriate prescriptions sending hospitalized seniors back to the ER
Improving hospital prescribing practices may reduce risk of rehospitalization and death
Canada Research Chairs Program announces new and renewed chairs
Congratulations to five RI-MUHC researchers in the spring 2020 round!
With Veterans Affairs Canada, Dr. Steven Grover and his team are getting Canadian families moving
The summer Family Fitness Mission
Early treatment trial of hydroxychloroquine shows no symptomatic benefit for COVID-19 patients
Adult outpatients with mild symptoms of COVID-19 don’t benefit from taking hydroxychloroquine